First patients dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Ph 1/2a studies in neuroendocrine tumors and solid tumors
The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company’s ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). This cohort explores optimizing a 20 mCi cumulative dose by front-loading, with 6.0 mCi in the first dose, 5.0 mCi in the second dose, 5.0 mCi in the third dose, and 4.0 mCi in the fourth dose. The design of this dosing regimen will help determine whether front-loading could change response kinetics and further improve response rate and tolerability at the same cumulative administered dose.
Share:
More News
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “HER2-directed therapies have already transformed care for certain HER2-expressing cancers, including breast and gastric cancers. However, many other cancers overexpress HER2, and targeted treatment options remain unavailable for most of these tumour types. This positive CHMP opinion underscores the importance
“Today’s acceptance of the supplemental BLA represents an important milestone for ImmunityBio and for patients with BCG-unresponsive NMIBC,” said Richard Adcock, President and CEO of ImmunityBio. “ANKTIVA is already approved for patients with CIS with or without papillary disease, and this application has the potential to expand access to patients
“FDA Orphan Drug Designation for CLN-049 emphasizes both the urgent need for new therapies for people living with relapsed or refractory acute myeloid leukemia – including patients with TP53-mutated AML who currently face a particularly poor prognosis – and the potential of this FLT3-directed T cell engager to expand treatment
“This proposed transaction represents a transformational opportunity for Liminatus to expand into next-generation oncology cell therapies,” said Chris Kim, Chief Executive Officer of Liminatus Pharma. “InnocsAI’s portfolio includes differentiated CAR-T technologies designed to address major limitations in current cancer therapies, including antigen escape, tumor heterogeneity, and the immunosuppressive tumor microenvironment.